Search results
The McClymonts’ Samantha McClymont Is Battling Breast Cancer
Billboard via Yahoo News· 2 days ago“Last October, I found a lump,” she writes. “After initially being misdiagnosed,” she continues, her...
G1 Therapeutics Inc (GTHX) Q1 2024 Earnings: Close Alignment with Analyst Revenue Projections
GuruFocus.com via Yahoo Finance· 2 days agoIts flagship product, COSELA (trilaciclib), is designed to protect bone marrow from chemotherapy...
G1 Therapeutics Inc (GTHX) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth ...
GuruFocus.com via Yahoo Finance· 21 hours agoG1 Therapeutics Inc (NASDAQ:GTHX) is making progress in clinical trials, with promising results in Phase 2 trials and upcoming data readouts that could enhance its market position in
'I just didn't expect it': Two young women describe breast cancer diagnoses
WLWT-TV Cincinnati· 4 hours agoOne in eight women in the United States will be diagnosed with breast cancer in her lifetime. Days...
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 13 hours agoG1 Therapeutics, Inc. (NASDAQ:GTHX) Q1 2024 Earnings Call Transcript May 1, 2024 G1 Therapeutics,...
For Reality Star Kimmi Grant Scott, Breast Cancer Wasn’t the End — It Was a New Beginning
SheKnows· 4 days agoAfter casually running her hand across her right breast, Scott found a lump that was later diagnosed...
BioNTech (BNTX) to Release Earnings on Monday
ETF DAILY NEWS· 4 days agoBioNTech (NASDAQ:BNTX – Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens on Monday, May 6th. Analysts expect BioNTech to post earnings of ($0.45 ...
Klineo wins €2m to advance AI patient recruitment platform
Clinical Trials Arena via Yahoo Finance· 4 days agoIn 2022, Klineo launched the first national platform in France for triple-negative breast cancer in...
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights - G1...
Benzinga· 2 days ago- Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated Efficacy Results
Earnings call: G1 Therapeutics reports growth and optimistic outlook By Investing.com
Investing.com· 1 day agoG1 Therapeutics (NASDAQ:GTHX) has reported promising financial results in their first-quarter...